Faeth Therapeutics reports 33% response rate in Phase 2 endometrial cancer trial
Faeth Therapeutics announced that its Phase 2 PIKTOR trial in advanced endometrial cancer achieved a confirmed objective response rate of 33% and a disease‑control rate of 83%. Median progression‑free survival was 7.4 months, with 62% of patients progression‑free at six months. The company said it will move the regimen into a Phase 3 registrational study pending regulatory discussions.
Why it matters
The company’s plan to initiate Phase 3 testing could unlock future revenue if the regimen receives approval, and the data may lift investor sentiment toward the stock (the company says the findings support Phase 3 planning,; the advance is subject to regulatory alignment,).
Key facts
- 1Confirmed objective response rate was 33% (12 of 36 efficacy‑evaluable patients). investing.com
- 2Disease‑control rate was 83%. investing.com
- 3Median progression‑free survival was estimated at 7.4 months. investing.com
- 462% of patients were progression‑free at six months. investing.com
- 5Among patients with a PIK3CA mutation, the confirmed response rate was 44% (7 of 16 patients). investing.com
- 6The trial enrolled 42 treated patients, who had a median of two prior lines of therapy. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.